nach oben

Medical Oncology

Erschienen in:

01.09.2023 | Original Paper

LHPP suppresses proliferation, migration, and invasion in hepatocellular carcinoma and pancreatic cancer by inhibiting EGFR signaling pathway

verfasst von: Haitao Zhu, Chunzhuo Song, Junjun Li, Qianfan Liu, Meng Liu, Liyue Fu

Erschienen in: Medical Oncology | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Abstract

Phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP) has been reported to be a new tumor suppressor with a significant inhibitory effect in various cancers. Although LHPP has been repeatedly shown to inhibit the progression of various tumors by inhibiting the phosphorylation of AKT, up to now, the studies on the function and mechanism of LHPP in tumors are insufficient. In this study, LHPP expression was found to be downregulated in both hepatocellular carcinoma (HCC) and pancreatic cancer (PC). Here, we found that LHPP could bind to epidermal growth factor receptor (EGFR) and inhibit its phosphorylation, which thereby inhibited the activation of EGFR downstream pathways ERK, AKT, and STAT3, and then weakening the ability to proliferate, invade, and migrate in HCC and PC. This paper showed a new physiological function of LHPP in inhibiting phosphorylation of EGFR and its potential anti-tumor mechanism and indicated that LHPP was a potential therapeutic target for HCC and PC.

Hindupur S, et al. The protein histidine phosphatase LHPP is a tumour suppressor. Nature. 2018;555(7698):678–82.PubMedPubMedCentralCrossRef

Ma L, et al. Tumor suppressor LHPP suppresses cell proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma cell lines. J Physiol Biochem. 2022;78:807–17.PubMedCrossRef

Liao L, et al. LHPP inhibits hepatocellular carcinoma cell growth and metastasis. Cell Cycle (Georgetown, Tex). 2020;19(14):1846–54.PubMedCrossRef

Liu S, et al. As a novel tumor suppressor, LHPP promotes apoptosis by inhibiting the PI3K/AKT signaling pathway in oral squamous cell carcinoma. Int J Biol Sci. 2022;18(2):491–506.PubMedPubMedCentralCrossRef

Lin J, et al. m6A methylation mediates LHPP acetylation as a tumour aerobic glycolysis suppressor to improve the prognosis of gastric cancer. Cell Death Dis. 2022;13(5):463.PubMedPubMedCentralCrossRef

Chen W, et al. LHPP impedes energy metabolism by inducing ubiquitin-mediated degradation of PKM2 in glioblastoma. Am J Cancer Res. 2021;11(4):1369–90.PubMedPubMedCentral

Li C, et al. LHPP exerts a tumor-inhibiting role in glioblastoma via the downregulation of Akt and Wnt/β-catenin signaling. J Bioenerg Biomembr. 2021;53(1):61–71.PubMedCrossRef

Wang D, et al. LHPP suppresses tumorigenesis of intrahepatic cholangiocarcinoma by inhibiting the TGFβ/smad signaling pathway. Int J Biochem Cell Biol. 2021;132: 105845.PubMedCrossRef

Hou B, et al. LHPP suppresses colorectal cancer cell migration and invasion in vitro and in vivo by inhibiting Smad3 phosphorylation in the TGF-β pathway. Cell Death Discov. 2021;7(1):273.PubMedPubMedCentralCrossRef

10.

Hou B, et al. Tumor suppressor LHPP regulates the proliferation of colorectal cancer cells via the PI3K/AKT pathway. Oncol Rep. 2020;43(2):536–48.PubMed

11.

Li Z, et al. Purpurin binding interacts with LHPP protein that inhibits PI3K/AKT phosphorylation and induces apoptosis in colon cancer cells HCT-116. J Biochem Mol Toxicol. 2021;35(3): e22665.PubMedCrossRef

12.

Sun W, et al. LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway. Acta Biochim Biophys Sin. 2020;52(4):382–9.PubMedCrossRef

13.

Wu F, Chen Y, Zhu J. LHPP suppresses proliferation, migration, and invasion and promotes apoptosis in pancreatic cancer. 2020. Biosci Rep. https://doi.org/10.1042/BSR20194142.

14.

Li Y, et al. LHPP suppresses bladder cancer cell proliferation and growth via inactivating AKT/p65 signaling pathway. 2019. Biosci Rep. https://doi.org/10.1042/BSR20182270.

15.

Zheng J, et al. Down-regulation of LHPP in cervical cancer influences cell proliferation, metastasis and apoptosis by modulating AKT. Biochem Biophys Res Commun. 2018;503(2):1108–14.PubMedCrossRef

16.

Zhang X, et al. LHPP inhibits the proliferation and metastasis of renal cell carcinoma. Biomed Res Int. 2020;2020:7020924.PubMedPubMedCentralCrossRef

17.

Zhang H, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Investig. 2007;117(8):2051–8.PubMedPubMedCentralCrossRef

18.

Shia J, et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Modern Pathol. 2005;18(10):1350–6.CrossRef

19.

OuYang Y, et al. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors. Eur J Med Chem. 2018;154:29–43.PubMedCrossRef

20.

Wang X, et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res. 2007;13(3):953–7.PubMedCrossRef

21.

Sun X, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present). Expert Opin Ther Pat. 2021;31(3):223–38.PubMedCrossRef

22.

Kil S, Carlin C. EGF receptor residues leu(679), leu(680) mediate selective sorting of ligand-receptor complexes in early endosomal compartments. J Cell Physiol. 2000;185(1):47–60.PubMedCrossRef

23.

Ito Y, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001;84(10):1377–83.PubMedPubMedCentralCrossRef

24.

Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3–20.PubMedCrossRef

25.

Liu J, et al. Long noncoding RNA MYLK-AS1 promotes growth and invasion of hepatocellular carcinoma through the EGFR/HER2-ERK1/2 signaling pathway. Int J Biol Sci. 2020;16(11):1989–2000.PubMedPubMedCentralCrossRef

26.

Walsh N, et al. EGFR and HER2 inhibition in pancreatic cancer. Invest New Drugs. 2013;31(3):558–66.PubMedCrossRef

27.

Bloomston M, et al. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg. 2006;23:74–9.PubMedCrossRef

28.

Panvichian R, et al. Missense mutations in exons 18–24 of EGFR in hepatocellular carcinoma tissues. Biomed Res Int. 2015;2015: 171845.PubMedPubMedCentralCrossRef

29.

Shi K, et al. Emerging strategies to overcome resistance to third-generation EGFR inhibitors. J Hematol Oncol. 2022;15(1):94.PubMedPubMedCentralCrossRef

30.

Ramani S, Samant S, Manohar S. The story of EGFR: from signaling pathways to a potent anticancer target. Future Med Chem. 2022. https://doi.org/10.4155/fmc-2021-0343.CrossRefPubMed

31.

Yu J, et al. Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers. Front Mol Biosci. 2022;9: 847835.PubMedPubMedCentralCrossRef

32.

Chong C, Jänne P. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19(11):1389–400.PubMedPubMedCentralCrossRef

33.

Mok T, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.PubMedCrossRef

34.

Han J, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122–8.PubMedCrossRef

35.

Mitsudomi T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8.PubMedCrossRef

36.

Maemondo M, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.PubMedCrossRef

37.

Zhou C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.PubMedCrossRef

38.

Rosell R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.PubMedCrossRef

39.

Sequist L, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34.PubMedCrossRef

40.

Wu Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–22.PubMedCrossRef

41.

Soria J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25.PubMedCrossRef

42.

Heinemann V, et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the “Arbeitsgemeinschaft Internistische Onkologie” (AIO-PK0104). Gut. 2013;62(5):751–9.PubMedCrossRef

43.

Vickers M, et al. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer (Oxford, England). 2012;48(10):1434–42.CrossRef

44.

Zhang G, et al. CD317 activates EGFR by regulating its association with lipid rafts. Can Res. 2019;79(9):2220–31.CrossRef

45.

Cai S, et al. Reduced kinase D-interacting substrate of 220 kDa (Kidins220) in pancreatic cancer promotes EGFR/ERK signalling and disease progression. Int J Oncol. 2021. https://doi.org/10.3892/ijo.2021.5214.CrossRefPubMedPubMedCentral

46.

Fatima I, et al. MASTL regulates EGFR signaling to impact pancreatic cancer progression. Oncogene. 2021;40(38):5691–704.PubMedPubMedCentralCrossRef

47.

Kaushik G, et al. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. Oncogene. 2021;40(4):848–62.PubMedCrossRef

48.

Bonomi P, et al. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018;29(8):1701–9.PubMedPubMedCentralCrossRef

49.

Mohan N, et al. A novel bispecific antibody targeting EGFR and VEGFR2 is effective against triple negative breast cancer via multiple mechanisms of action. Cancers. 2021;13(5):1027.PubMedPubMedCentralCrossRef

50.

Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res. 2021;40(1):328.PubMedPubMedCentralCrossRef

51.

Levantini E, et al. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022. https://doi.org/10.1016/j.semcancer.2022.04.002.CrossRefPubMed

Titel: LHPP suppresses proliferation, migration, and invasion in hepatocellular carcinoma and pancreatic cancer by inhibiting EGFR signaling pathway
verfasst von: Haitao Zhu
Chunzhuo Song
Junjun Li
Qianfan Liu
Meng Liu
Liyue Fu
Publikationsdatum: 01.09.2023
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 9/2023
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-023-02127-1

Springer Medizin

LHPP suppresses proliferation, migration, and invasion in hepatocellular carcinoma and pancreatic cancer by inhibiting EGFR signaling pathway

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2023

The mechanistic insights of the antioxidant Keap1-Nrf2 pathway in oncogenesis: a deadly scenario

EGCG attenuate EGF triggered matrix abundance and migration in HPV positive and HPV negative cervical cancer cells

Advanced nano-therapeutic delivery of metformin: potential anti-cancer effect against human colon cancer cells through inhibition of GPR75 expression

Exosomal non-coding RNAs-mediated EGFR-TKIs resistance in NSCLC with EGFR mutation

Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma

SETD2 controls m6A modification of transcriptome and regulates the molecular oncogenesis of glioma

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie